93 related articles for article (PubMed ID: 31493661)
1. Structure based virtual screening of natural products to disrupt the structural integrity of TRAF6 C-terminal domain homotrimer.
Biswas R; Chowdhury N; Biswas S; Roy R; Bagchi A
J Mol Graph Model; 2019 Dec; 93():107428. PubMed ID: 31493661
[TBL] [Abstract][Full Text] [Related]
2. Identification and analyses of natural compounds as potential inhibitors of TRAF6-Basigin interactions in melanoma using structure-based virtual screening and molecular dynamics simulations.
Biswas R; Chowdhury N; Mukherjee R; Bagchi A
J Mol Graph Model; 2018 Oct; 85():281-293. PubMed ID: 30253283
[TBL] [Abstract][Full Text] [Related]
3. A structural perspective on the interactions of TRAF6 and Basigin during the onset of melanoma: A molecular dynamics simulation study.
Biswas R; Ghosh S; Bagchi A
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28612997
[TBL] [Abstract][Full Text] [Related]
4. Structural Characterization of the Trimerization of TRAF6 Protein Through Molecular Dynamics Simulations.
Biswas R; Bagchi A
Interdiscip Sci; 2019 Sep; 11(3):428-436. PubMed ID: 28895065
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of TRAF6-Ubc13 interaction in NFkB inflammatory pathway by analyzing the hotspot amino acid residues and protein-protein interactions using molecular docking simulations.
Biswas R; Bagchi A
Comput Biol Chem; 2017 Oct; 70():116-124. PubMed ID: 28869835
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
[TBL] [Abstract][Full Text] [Related]
7. In silico investigation of potential TRAF6 inhibitor from traditional Chinese medicine against cancers.
Chen KC; Lee WY; Chen HY; Chen CY
Biomed Res Int; 2014; 2014():429486. PubMed ID: 25089269
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Development of a Protein-Protein Interaction Inhibitor Targeting Tumor Necrosis Factor Receptor-Associated Factor 6.
Moriya J; Takeuchi K; Tai K; Arai K; Kobayashi N; Yoneda N; Fukunishi Y; Inoue A; Kihara M; Murakami T; Chiba K; Shimada I
J Med Chem; 2015 Jul; 58(14):5674-83. PubMed ID: 26132273
[TBL] [Abstract][Full Text] [Related]
9. Structure, interactions, and dynamics of the RING domain from human TRAF6.
Mercier P; Lewis MJ; Hau DD; Saltibus LF; Xiao W; Spyracopoulos L
Protein Sci; 2007 Apr; 16(4):602-14. PubMed ID: 17327397
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of ubiquitin transfer promoted by TRAF6.
Fu TM; Shen C; Li Q; Zhang P; Wu H
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1783-1788. PubMed ID: 29432170
[TBL] [Abstract][Full Text] [Related]
11. A Dithiol Compound Binds to the Zinc Finger Protein TRAF6 and Suppresses Its Ubiquitination.
Koga R; Radwan MO; Ejima T; Kanemaru Y; Tateishi H; Ali TFS; Ciftci HI; Shibata Y; Taguchi Y; Inoue JI; Otsuka M; Fujita M
ChemMedChem; 2017 Dec; 12(23):1935-1941. PubMed ID: 28884970
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo cancer cell apoptosis triggered by competitive binding of Cinchona alkaloids to the RING domain of TRAF6.
Qi Y; Zhao X; Chen J; Pradipta AR; Wei J; Ruan H; Zhou L; Hsung RP; Tanaka K
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1011-1026. PubMed ID: 31074699
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumor cell proliferation by quinine via the inhibition of the tumor necrosis factor receptor‑associated factor 6‑AKT interaction.
Liu W; Qi Y; Liu L; Tang Y; Wei J; Zhou L
Mol Med Rep; 2016 Sep; 14(3):2171-9. PubMed ID: 27430155
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for the unique specificity of TRAF6.
Chung JY; Lu M; Yin Q; Lin SC; Wu H
Adv Exp Med Biol; 2007; 597():122-30. PubMed ID: 17633022
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of the RING domain from human TRAF6 by 15N NMR spectroscopy: implications for biological function.
Markin CJ; Saltibus LF; Spyracopoulos L
Biochemistry; 2008 Sep; 47(38):10010-7. PubMed ID: 18759459
[TBL] [Abstract][Full Text] [Related]
16. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
17. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
18. Natural small molecule FMHM inhibits lipopolysaccharide-induced inflammatory response by promoting TRAF6 degradation via K48-linked polyubiquitination.
Zeng KW; Liao LX; Lv HN; Song FJ; Yu Q; Dong X; Li J; Jiang Y; Tu PF
Sci Rep; 2015 Oct; 5():14715. PubMed ID: 26423026
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity.
Hu L; Xu J; Xie X; Zhou Y; Tao P; Li H; Han X; Wang C; Liu J; Xu P; Neculai D; Xia Z
Nat Commun; 2017 Oct; 8(1):814. PubMed ID: 28993672
[TBL] [Abstract][Full Text] [Related]
20. Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach.
Ambure P; Bhat J; Puzyn T; Roy K
J Biomol Struct Dyn; 2019 Mar; 37(5):1282-1306. PubMed ID: 29578387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
